Z Radical Contains Nitrogen Patents (Class 514/551)
  • Patent number: 10252989
    Abstract: The invention relates to picolinamides of Formula I and their use as fungicides.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 9, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Chenglin Yao, Kevin G. Meyer, Yu Lu, Brian A. Loy, David M. Jones, Ronald J. Heemstra, Jeffrey B. Epp, Johnathan E. Delorbe, Kyle A. Dekorver, John F. Daeuble, Sr.
  • Patent number: 10010513
    Abstract: The present invention is directed to an aqueous pharmaceutical composition, particularly an aqueous ophthalmic composition, suitable as an injection, particularly an intravitreal injection. The composition includes a biologic therapeutic agent (e.g., an isolated monoclonal antibody that specifically binds to a C5 protein) that tends to raise the viscosity of the composition and a guanidine and/or guanidine derivative (e.g., L-arginine) that tends to lower the viscosity of the composition.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: July 3, 2018
    Assignee: Novartis AG
    Inventors: David Schmitt, Hans-Joachim Wallny
  • Patent number: 9975847
    Abstract: Provided are compounds described by the Formula I: wherein: R1 is a linear or branched, saturated or unsaturated aliphatic group having from 5 to 22 carbon atoms; R2 is selected from the group consisting of the functional groups: and salts thereof; n is from 0 to 4; and R3 is a linear or branched, saturated or unsaturated aliphatic group having from 1 to 6 carbon atoms. Also provided are compositions comprising, and methods of use of, the compounds of the present invention.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: May 22, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Robert J. Gambogi, Anthony R. Geonnotti, III, Michael C. Giano, Latrisha Petersen
  • Patent number: 9956190
    Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: May 1, 2018
    Assignee: VIZURI HEALTH SCIENCES LLC
    Inventors: Philip J. Birbara, Daniel Bucks
  • Patent number: 9883923
    Abstract: Disclosed are endodontic filling materials and methods. A method for filling a dental root canal may include providing a hydrosetting filling material and inserting the hydrosetting filling material into the dental root canal, the material setting in the root canal to form a biocompatible filling. The hydrosetting filling material comprises a hydrogel former and a filler. The hydrogel former is at least one of a reactive organic hydrogel formers, an inorganic hydrogel formers, and a non-reactive organic hydrogel formers, and the filler is at least one of a self-hardening and a non-hardening filler. Plural filling material precursor compositions that collectively contain hydrogel formers and fillers may be provided.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 6, 2018
    Assignee: AMERICAN DENTAL ASSOCIATION FOUNDATION
    Inventors: Laurence C Chow, Shozo Takagi
  • Patent number: 9573882
    Abstract: New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: February 21, 2017
    Assignee: JSC GRINDEKS
    Inventors: Ivars Kalvins, Maija Dambrova, Edgars Liepins, Osvalds Pugovics, Reinis Vilskersts, Janis Kuka, Solveiga Grinberga, Einars Loza
  • Patent number: 9278907
    Abstract: New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 8, 2016
    Assignee: JSC GRINDEKS
    Inventors: Ivars Kalvins, Maija Dambrova, Edgars Liepins, Osvalds Pugovics, Reinis Vilskersts, Janis Kuka, Solveiga Grinberga, Einars Loza
  • Patent number: 9085508
    Abstract: There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid derivative thereof and a nitric oxide releasing group as depicted in the following structures: wherein R1 is either an ethyl or an amino acid side-chain group or an amino acid derivative thereof and R2 is an amino acid side-chain group or an amino acid derivative thereof and n is an integer from 1 to 10.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: July 21, 2015
    Assignee: Oral Delivery Technology Ltd.
    Inventor: Michael Farber
  • Patent number: 9040261
    Abstract: A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 26, 2015
    Assignee: NEW YORK UNIVERSITY
    Inventors: Michael D. Ward, Jeffrey Rimer
  • Publication number: 20150133408
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.
    Type: Application
    Filed: February 16, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh KANDULA
  • Patent number: 9011896
    Abstract: The present invention is related to scoring or cutting balloon catheters carrying at least on a portion of their surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one lipophilic antioxidant in relation to 100% by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiaretic acid, resveratrol and propyl gallate.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: April 21, 2015
    Assignee: AngioScore, Inc.
    Inventors: Ulrich Speck, Madeleine Caroline Berg
  • Patent number: 9012502
    Abstract: Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3??(1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: April 21, 2015
    Assignees: SBI Pharmaceuticals Co., Ltd., Tokyo University Agriculture Educational Corporation
    Inventors: Taku Chibazakura, Tohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe
  • Publication number: 20150099806
    Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Application
    Filed: December 14, 2014
    Publication date: April 9, 2015
    Inventors: Michael D. WARD, Zina ZHU
  • Publication number: 20150094314
    Abstract: A method of modulating ribonucleotide reductase activity in a neoplastic cell includes administering to the cell an amount of a ribonucleotide reductase allosteric modulator (RRAmod), the amount being effective to inhibit neoplastic cell growth.
    Type: Application
    Filed: March 21, 2013
    Publication date: April 2, 2015
    Inventor: Chris Dealwis
  • Publication number: 20150080466
    Abstract: The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Publication number: 20150079163
    Abstract: The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 19, 2015
    Inventors: Bassam B. DAMAJ, Richard Martin
  • Publication number: 20150073051
    Abstract: An antimicrobial composition is provided that includes from about 0.1 to about 2 wt. % of a cationic antimicrobial agent selected from the group consisting of lauric arginate and benzalkonium chloride, based upon the total weight of the antimicrobial composition; from about 1 to about 10 wt. % of two or more nonionic surfactants selected from the group consisting of glucoside alkyl ethers and poloxamers, based upon a total weight of the antimicrobial composition; from about 0.1 to about 5 wt. % of an amine oxide, based upon the total weight of the antimicrobial composition; and one or more preservatives selected from phenoxyethanol, ethylhexyl glycerin, hexylene glycol, caprylyl glycol, and mixtures thereof.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 12, 2015
    Inventors: Mitchell Cohen, James Bingham
  • Publication number: 20150038581
    Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.
    Type: Application
    Filed: March 6, 2014
    Publication date: February 5, 2015
    Inventors: James Elliot Bradner, Ralph Mazitschek
  • Publication number: 20150031761
    Abstract: The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the photodynamic treatment or diagnosis of cancer, an infection associated with cancer, or in the treatment or diagnosis of a non-cancerous condition, wherein said pharmaceutical product is in the form of a solid. The invention also relates to solid pharmaceutical products for use in such methods, e.g. suppositories, pessaries, tablets, pellets and capsules which comprise 5-ALA or a precursor or derivative thereof (e.g. an ALA ester) and at least one pharmaceutically acceptable carrier or excipient. Such products are particularly suitable for use in the photodynamic treatment or diagnosis of cancerous or non-cancerous conditions in the lower part of the gastrointestinal system or in the female reproductive system, e.g. in the treatment or diagnosis of colorectal cancer or cervical cancer.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 29, 2015
    Inventors: Jo Klaveness, Gry Stensrud, Aslak Godal, Jon Erik Braenden, Bjorn Klem
  • Publication number: 20150030669
    Abstract: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 29, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Michael Wilhelm Platscher, Raymond Behrendt, Viola Groehn, Simone Rachel Hoertner, Marco Silvio Passafaro, Finn Bauer
  • Patent number: 8933122
    Abstract: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may originate from bacteria or fungi.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: January 13, 2015
    Assignee: Laboratorios Miret, S.A.
    Inventors: Xavier Rocabayera Bonvila, Sergi Figueras Roca, Roger Segret Pons, Eva Piera Eroles
  • Patent number: 8927761
    Abstract: This invention relates to a novel crystalline polymorph of hexyl-5-aminolevulinate hydrochloride, referred to hereinafter as Form C, which is useful as precursor of a photo sensitizer in the photodynamic diagnosis and treatment of metabolically active cells related to diseases such as cancer of the uterus, cervix, vagina, rectum, colon, lower gastrointestinal tract; infection associated with cancer caused by human papilloma virus; non-cancerous lower gastrointestinal tract a human; inflammatory bowel disease; ulcerative colitis; Crohn's disease; inflammatory bowel syndrome; dysplasia of the female reproductive system; anus; penis; rosacea; and acne and which is suitable for use as the active ingredient of a commercial pharmaceutical product. The invention relates further to methods of preparing Form C and using it in the described pharmaceutical compositions.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: January 6, 2015
    Assignee: Photocure ASA
    Inventors: Stephan D. Parent, Jon Erik Brænden
  • Patent number: 8921421
    Abstract: The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of 3 to 6; R1 is selected from the group of structures (i-vii), wherein R2, R3 and R4 are selected from the group consisting of hydrogen, an alkyl or aryl radical, R5 and R6 are selected from the group consisting of hydrogen, a hydrocarbon chain having a chain length of 1 to 8 and an aryl radical, R7, R8, R9 and R10 are selected from the group consisting of hydrogen, and alkyl or aryl radical; W is oxygen (O) or nitrogen (N); and X is a methylene group (CH2) or a secondary amino group (NH); Y is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromat
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: December 30, 2014
    Assignee: Christian-Albrechts-Universitaet Zu Kiel
    Inventors: Bernd Clement, Jürke Kotthaus, Dennis Schade
  • Publication number: 20140357713
    Abstract: The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.
    Type: Application
    Filed: May 7, 2014
    Publication date: December 4, 2014
    Applicant: NexMed Holdings, Inc.
    Inventors: Bassam B. Damaj, Richard Martin
  • Patent number: 8900625
    Abstract: The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 2, 2014
    Assignee: Nexmed Holdings, Inc.
    Inventors: Bassam B. Damaj, Richard M. Martin
  • Patent number: 8865687
    Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: October 21, 2014
    Assignee: N.V. Nutricia
    Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
  • Publication number: 20140309302
    Abstract: A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided and includes [A] one or more undecylenic acid derivatives depicted by Formula (I), [B] one or more octanoic acid derivatives depicted by Formula (II), and [C] 2-phenoxy ethanol or 2-ethyl hexyl glyceryl ether or mixture of these two ‘liquid alcohol ethers’; wherein, each of the two components [A] and [B] is present in the range of 5 to 20% by weight and together [A] and [B] constitute 10 to 30% by weight and the ‘liquid alcohol ether’, component [C], is present 70 to 90% by weight of the total preservative composition. A method for preserving personal care product from microbial attack is provided containing an aqueous phase comprising three component composition from about 0.5 to 2.5% by weight of the total personal care formulation.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 16, 2014
    Applicant: Galaxy Surfactants Ltd.
    Inventors: Nirmal Koshti, Shraddha Kiran Ratnaparkhe, Devyani Ashok Mali, Bhagyesh Sawant, Pooja Dinkar Vaidya
  • Publication number: 20140309273
    Abstract: Provided are new fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, e.g., as agents for the treatment of obesity and related disorders, and for improving cognition.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., AL-QUDS UNIVERSITY
    Inventors: Jehoshua KATZHENDLER, Meir SAIDIAN, Yousef NAJAJREH, Raphael MEVORACH, Elliot BERRY, Yosefa AVRAHAM
  • Publication number: 20140303100
    Abstract: This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 9, 2014
    Inventors: Anthony Errol Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Patent number: 8846723
    Abstract: Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C3-C8 cycloalkyl, substituted and unsubstituted C6-C20 carbocyclic aryl, and substituted and unsubstituted C4-C20 heterocyclic; wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and wherein n is 1-6. Process of producing esters of O-substituted hydroxy carboxylic acids are also provided.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: September 30, 2014
    Assignees: Eastman Chemical Company, Chanel Parfums Beaute
    Inventors: Liu Deng, Neil Warren Boaz, Sabine Delaire
  • Publication number: 20140288144
    Abstract: A compound of formula (I): R?—O-A-O—R??, in which R? and R? are a hydrogen atom or a monovalent radical of formula (IIa), or a monovalent radical of formula (IIb), it being understood that at least one of the radicals R? or R? is not a hydrogen atom and that, when none of the radicals R? and R? is a hydrogen atom, R? and R? are identical, and in which A is a divalent radical of formula (III): —CH(X1)-[C(X2)(X3)]p-CH(X4) in which X1, X2, X3 and X4 are identical or different and are either a hydrogen atom or a methyl radical or an ethyl radical, and p is an integer greater than or equal to 1 and less than or equal to 6. Also the method for preparing the compound of formula (I) and to the use thereof in cosmetics and as a drug.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 25, 2014
    Applicant: Societe D'Exploitation de Produits Pour Les Industries Chimiques Seppic
    Inventors: Sandy Dumont, Jerome Guilbot, Stephanie Garcel, Laetitia Cattuzzato
  • Publication number: 20140288142
    Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Inventors: Nicoletta ALMIRANTE, Stefano BIONDI, Ennio ONGINI, Laura STORONI, Alessia NICOTRA
  • Patent number: 8834857
    Abstract: A method for cleaning, benefiting, or deodorizing skin or hair utilizing a body wash, skin cleaner, soap, shampoo or deodorizer formulation containing a controlled release skin benefit or deodorizing salt, a hydrophilic moisturizing polymer and surfactants is described. The method imparts benefits or deodorizing agents to the skin or hair and maintains effective levels for an extended period.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: September 16, 2014
    Assignee: Nevada Naturals Inc.
    Inventors: Anthony E. Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140221316
    Abstract: This disclosure relates to novel compounds containing an H2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H2S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.
    Type: Application
    Filed: August 15, 2012
    Publication date: August 7, 2014
    Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Khosrow Kashfi, Ravinder Kodela
  • Patent number: 8795699
    Abstract: A method of repelling wasps, which method comprises using a preparation comprising (a) one or more of ethyl 3-(N-n-butyl-N-acetylamino)propionate, dihydronepetalactone, and extract of catmint, and (b) at least one compound selected from certain perfume ingredients. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: August 5, 2014
    Assignee: Beiersdorf AG
    Inventors: Rainer Kroepke, Jens Schulz, Jens Nielsen, Stephanie Von Der Fecht
  • Publication number: 20140213620
    Abstract: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto.
    Type: Application
    Filed: July 17, 2013
    Publication date: July 31, 2014
    Inventors: James Elliot Bradner, Ralph Mazitschek
  • Publication number: 20140170207
    Abstract: The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 19, 2014
    Inventors: Bassam B. Damaj, Richard M. Martin
  • Publication number: 20140142156
    Abstract: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial.
    Type: Application
    Filed: December 12, 2013
    Publication date: May 22, 2014
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Helen E. BLACKWELL, Christine E. McINNIS
  • Publication number: 20140128827
    Abstract: A triggerable composition for two-stage, controlled release of a functional active chemical includes an encapsulation material for encapsulating a betaine ester or betaine ester derivative including a functional active. The encapsulation material is triggerable to release the betaine ester or betaine ester derivative at a first stage upon the occurrence with an environmental stimulus, such as a pH change, an enzymatic change, and a temperature change. The betaine ester or betaine ester derivative of a functional active with at least one hydroxyl group releases the functional active through a hydrolysis reaction upon contact with an aqueous medium.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 8, 2014
    Applicant: KIMBERLY-CLARK WORLDWIDE, INC.
    Inventor: Xuedong Song
  • Publication number: 20140121270
    Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
    Type: Application
    Filed: August 2, 2013
    Publication date: May 1, 2014
    Applicant: Run Them Sweet, LLC
    Inventors: Michael A. Horning, George A. Brooks
  • Publication number: 20140121269
    Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 1, 2014
    Applicant: Run Them Sweet, LLC
    Inventors: Michael A. Horning, George A. Brooks
  • Publication number: 20140100271
    Abstract: There is provided a compound of Formula (I) and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted alkyl group, where the aryl group is substituted, (c) an alkoxy substituted alkyl group, where the alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group, or (d) an H atom, where the substituents in (a) and (b) are hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo or fluoro groups. The compounds may be used as a medicament.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 10, 2014
    Applicant: Swedish Pharma AB c/o Inkubera AB
    Inventors: Leif A. ERIKSSON, Lennart LÖFGREN
  • Patent number: 8685887
    Abstract: The present application relates to surfactant compositions comprising a) at least one phosphated arylphenol alkoxylate surfactant having an average degree of alkoxylation of from 4-8; and b) at least one alkylamine alkoxylate surfactant having an average degree of alkoxylation of from 2-12 and to the use of these compositions in pesticide formulations comprising solid or encapsulated pesticidally active ingredients or formulation aids and methods for improving the re-suspension properties of pesticide suspensions.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: April 1, 2014
    Assignee: Syngenta Crop Protection LLC
    Inventors: Randall Charles Cush, Sarah Beth Cush, Michael James Hopkinson, Jason Keiper
  • Patent number: 8664247
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 4, 2014
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Publication number: 20140057787
    Abstract: Coating composition for soya bean seed from which roots and shoots are capable of growing, wherein the coating composition comprises an organic carrier material and one or more biological agents that possess an activity against at least one or more pathogens of the soybean plant.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 27, 2014
    Applicant: EXOSECT LIMITED
    Inventor: Nicholas Hugh Hylton Jessop
  • Publication number: 20140031403
    Abstract: The present invention provides forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms.
    Type: Application
    Filed: April 5, 2012
    Publication date: January 30, 2014
    Applicants: VAN ANDEL RESEARCH INSTITUTE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventors: Stephen T. Gately, Steven J. Triezenberg, Tong Wang
  • Publication number: 20140010761
    Abstract: This invention relates to a novel crystalline polymorph of hexyl-5-aminolevulinate hydrochloride, referred to hereinafter as Form C, which is useful as precursor of a photo sensitizer in the photodynamic diagnosis and treatment of metabolically active cells related to diseases such as cancer of the uterus, cervix, vagina, rectum, colon, lower gastrointestinal tract; infection associated with cancer caused by human papilloma virus; non-cancerous lower gastrointestinal tract a human; inflammatory bowel disease; ulcerative colitis; Crohn's disease; inflammatory bowel syndrome; dysplasia of the female reproductive system; anus; penis; rosacea; and acne and which is suitable for use as the active ingredient of a commercial pharmaceutical product. The invention relates further to methods of preparing Form C and using it in the described pharmaceutical compositions.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 9, 2014
    Applicant: PHOTOCURE ASA
    Inventors: Stephan D. Parent, Jon Erik Braenden
  • Publication number: 20130345171
    Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.
    Type: Application
    Filed: June 11, 2013
    Publication date: December 26, 2013
    Inventors: Stanley L. Hazen, Bruce Levison, Zeneng Wang
  • Publication number: 20130338227
    Abstract: Multifunctional green (eco-friendly) and antimicrobial compositions are described containing cationic glycine betaine esters and/or cationic glycine betaine amides. Particular glycine betaine esters and amides are alkyl(ene) betainate methane sulfonates and betainyl amino alkyl(ene) methane sulfonates. The glycine betaine components are cationic, have a hydrophobic group attached to a carboxylate group through an ester or amide linkage, and are derived from a natural source, such as sugar beets. The glycine betaine esters and amides serve as cationic surfactants which have effective antimicrobial activity. The surfactant compositions are effective as crude mixtures or semi-purified mixtures or purified surfactant compounds of glycine betaine components. The addition of sodium chloride or potassium chloride or magnesium chloride or natural gum or polysaccharide to compositions containing the cationic glycine betaine ester and/or glycine betaine amide derivatives serves to thicken or gel the composition.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 19, 2013
    Inventors: Marie-Esther SAINT VICTOR, Thierry Benvegnu, Hakima-Fatima Azira
  • Patent number: 8580852
    Abstract: The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA 2 and GVIA 1PLA 2) and one human secretory phospholipase A2 (GV sPLA 2) were evaluated. Derivatives containing a free carboxyl group are selective GIVA cPLA 2 inhibitors. A derivative based on the ethyl ester of an ether pseudodipeptide is the first 2-oxoamide, which preferentially inhibits GVIA iPLA 2. The effect of 2-oxoamides on the generation of arachidonic acid from RAW 264.7 macrophages was also studied. It was found that selective GIVA cPLA 2 inhibitors preferentially inhibited cellular arachidonic acid release; in which one pseudodipeptide gave an IC50 value of 2 ?M.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: November 12, 2013
    Assignee: The Regents of the University of California
    Inventors: Edward A. Dennis, George Kokotos, Violetta Constantinou-Kokotou